Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Neoplasms
Interventions: DRUG: ridaforolimus|DRUG: trastuzumab
Sponsor: Merck Sharp & Dohme LLC